Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) today reported results for the third quarter ended September 30, 2005. Net product revenues for the third quarter of 2005 totaled $30.3 million, compared to $18.0 million for the third quarter of 2004, up 69% year-over-year. CUBICIN continues to show strong revenue growth, with an 18% increase over the second quarter of 2005. Net loss for the third quarter of 2005 was $4.5 million, or $0.08 per share, compared to $17.7 million or $0.44 per share for the third quarter of 2004.
